EXHIBIT 99.1

FOR IMMEDIATE RELEASE:


                        ABMC Announces Management Changes

Kinderhook, N.Y., January 22, 2004 - American Bio Medica Corporation
(Nasdaq:ABMC) announced today that Donal V. Carroll has been removed from the
position of chief executive officer, effective January 21, 2004. He had held the
position since October, 2003. Mr. Carroll continues to serve as a member of the
Company's Board of Directors.

While the Company looks for a successor, the Executive Committee of the Board of
Directors will work closely with ABMC's Chief Financial Officer Keith Palmer,
Chief Scientific Officer Martin Gould, and Vice President of Sales and Marketing
Todd Bailey, in the day-to-day management of the Company.

Edmund Jaskiewicz, President of ABMC and a member of the Executive Committee of
the Board stated: "Immediate action was necessary to insure our objective of
continued sales and earnings growth in this quarter as well as the remainder of
2004. ABMC is committed to maximizing shareholder value by continuing to
strengthen the fundamentals of our Company."

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops,
manufactures and markets accurate, cost-effective immunoassay diagnostic test
kits, including some of the world's most effective point-of-collection tests for
drugs of abuse. The Company and its worldwide distribution network target the
workplace, government, corrections, clinical and educational markets. ABMC's
Rapid Drug Screen(R), Rapid One(R), Rapid Tec(R) and Rapid Tec Cup(TM) products
test for the presence or absence of drugs of abuse in urine, while OralStat(R)
tests for the presence or absence of drugs of abuse in saliva. ABMC has been
named among the 2002 Deloitte & Touche Technology Fast 500, a listing of the
fastest-growing technology companies in North America.

This release may contain forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results to
differ, and such differences could be material. Such risks and uncertainties
include, but are not limited to, the following: continued acceptance of the
Company's products, increased levels of competition in our industry, the
acceptance of new products, inherent risks associated with product development
and intellectual property rights, the Company's dependence on key personnel,
third party sales and suppliers. There can be no assurance that the Company will
be successful in addressing such risks and uncertainties and the Company assumes
no duty to update any forward-looking statements based upon actual results.
Investors are strongly encouraged to review the section entitled "Risk Factors"
in the Company's annual report on Form 10-KSB for the fiscal year ended December
31, 2002, and quarterly reports on Form 10-QSB on file with the Securities and
Exchange Commission for a discussion of risks and uncertainties that could
affect operating results and the market price of the Company's common shares.

                                      # # #